GeoVax Labs Inc. (OTCMKTS:GOVX) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.
GeoVax Labs (OTCMKTS GOVX) opened at $0.07 on Friday. GeoVax Labs has a 12 month low of $0.02 and a 12 month high of $0.10.
GeoVax Labs (OTCMKTS:GOVX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The firm had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.30 million. sell-side analysts forecast that GeoVax Labs will post -0.04 EPS for the current fiscal year.
GeoVax Labs, Inc (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for GeoVax Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.